

AN ACTIVE THERAPEUTIC COMPOUNDS SCREENING TOOL

PREVENTING THE ADVERSE EFFECTS OF REACTIVE OXYGEN SPECIES



- ▮ **Type of technology:** platform/screening
- ▮ **Targets:** Oxidative stress-related diseases and disorders, such as Colon Cancer, etc.
- ▮ **Unique Selling Point:** This High-throughput, genomics-based screening method that is superior to other existing methods for discovery of ROS type-specific antioxidants
- ▮ **Claim coverage:** Patent claims cover both pathways and individual genes

- Available for licensing
- Additional information is offered upon execution of a Confidentiality Disclosure Agreement

AN EFFECTIVE SCREENING METHOD

For testing active (therapeutic) compounds preventing or ameliorating the adverse effects of Reactive Oxygen Species in Colon Cancer

ADVANTAGES

This newly developed antioxidant screening technology offers a way to identify reactive oxygen species (ROS) type-specific antioxidants

-The one and only method for testing such compounds in a high throughput manner

- Innovative technology, patent application filed

-Disease-specific

-Faster than existing screening tools

Looking for efficient Reactive Oxygen Species compound screening tools?

During screening for therapeutic compounds, including antioxidants, screening tools for selecting reactive oxygen species (ROS) and detecting total cellular antioxidant activity are necessary.

However current assays hardly measure cellular effects of ROS, or independently evaluate the total cellular antioxidant activity. Therefore, up to now the combination of several tests are needed, such as TBARS, TEAC, Comet assays and Mass spectrometric detection for oxidized proteins.

We got the solution!

We have developed a gene expression profiles based ROS-screening tool.

Simple, Fast, High-Throughput

AN ACTIVE THERAPEUTIC COMPOUNDS SEARCHING TOOL

PREVENTING THE ADVERSE EFFECTS OF REACTIVE OXYGEN SPECIES

THE PATENT FACT

Method for Screening compounds for preventing the adverse effects of reactive oxygen species on Eukaryotic cells

Inventors: Jacco Briedé, PhD, Prof. Jos Kleinjans, PhD.

Netherlands Toxicogenomics Center (NTC)




Maastricht University Medical Center+ (MUMC+)

Time/Phase: 11 June 2009

Patent Code: EP09162498; WO/2010/142783

Available for licensing

Additional information is offered upon execution of CDA



You want more information? Contact us!

Jonathan de Jonge **T:** +31 (0)43 388 58 60, **E:** jonathan.dejonge@biomedbooster.com